Quote | VYNE Therapeutics Inc Com (NASDAQ:VYNE)
Last: | $2.57 |
---|---|
Change Percent: | -3.45% |
Open: | $2.4 |
Close: | $2.57 |
High: | $2.7305 |
Low: | $2.295 |
Volume: | 384,452 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | VYNE Therapeutics Inc Com (NASDAQ:VYNE)
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inf...
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investors Anticipate commencing a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q...
Message Board Posts | VYNE Therapeutics Inc Com (NASDAQ:VYNE)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $VYNE 26% v1,5M c.226 f58,035M H.23 ML.11 lod.16 | znewcar1 | investorshangout | 01/06/2023 10:08:06 PM |
znewcar1: VYNE 31% v42,8M c1.20 f53,5M H1.3 S1.1 | znewcar1 | investorshangout | 12/06/2021 9:23:34 PM |
The follow-on order took awhile but it did fill. | jugs | investorshub | 11/24/2020 8:38:31 PM |
Picked up 300 $VYNE today at $1.64. Just | jugs | investorshub | 11/24/2020 7:49:26 PM |
We will fix that when it's time for | jugs | investorshub | 11/24/2020 4:58:44 PM |
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inf...
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investors Anticipate commencing a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q...
Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201 BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceu...